Menu
biotium logo
Antibody Finder
Menu

DiR

DiR is a lipophilic, near-infrared fluorescent cyanine dye. The dye is useful for labeling cytoplasmic membranes and has been used for near-infrared in vivo imaging.

Size
Catalog #
price
Qty
5 x 1 mg
10 mg
Clear selection

Add to Cart
This product is available by special order only.

Please fill in the inquiry form and we will contact you shortly.

Product Description

DiR (DiIC18(7); 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide) is a lipophilic, near-infrared fluorescent cyanine dye. The dye is useful for labeling cytoplasmic membranes and has been used for near-infrared in vivo imaging. The two long 18-carbon chains insert into the cell membrane, resulting in specific and stable cell staining with no or minimal dye transfer between cells. A stock solution of the dye can be made in ethanol. Cell staining can be effected using the dye at 1-10 uM concentration and 10-20 min incubation time.

Please also see our CellBrite® Cytoplasmic Membrane Dyes & NIR Dyes available in a variety of colors.

  • λExEm (MeOH) = 748/780 nm
  • ε = 270,000
  • Dark blue-green oily solid soluble in ethanol, DMF or DMSO
  • Store at 4°C and protect from light
  • C63H101IN2
  • MW: 1013.4
  • [100068-60-8]

References

1. Biomaterials 34, 9171 (2013). http://dx.doi.org/10.1016/j.biomaterials.2013.08.039

2. J Control Release (2013) http://dx.doi.org/10.1016/j.jconrel.2013.10.002

3. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.09.094

4. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.09.089

5. International Journal of Nanomedicine 8, 2473–2485 (2013).

6. Bioconjugate Chemistry (2013) doi: 10.1021/bc400055h

7. International Journal of Pharmaceutics (2013), http://dx.doi.org/10.1016/j.ijpharm.2013.05.015

8. Pharm Res (2013) doi: 10.1007/s11095-013-1055-y

9. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.03.097

10. International Journal of Nanomedicine 8, 1573–1593 (2013)

11. International Journal of Nanomedicine 8, 1463–1476 (2013)

12. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.03.036

13. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.02.013

14. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2012.12.049

15. Biomaterials (2012), http://dx.doi.org/10.1016/j.biomaterials.2012.12.012

16. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2012.11.016

17. International Journal of Nanomedicine 7, 163–175 (2012)

18. J. Control. Release (2012) doi:10.1016/j.jconrel.2011.12.017

19. Pharm Res (2011) doi: 10.1007/s11095-011-0641-0

20. Biomaterials (2011) doi:10.1016/j.biomaterials.2011.10.035

21. International Journal of Pharmaceutics (2011) doi:10.1016/j.ijpharm.2011.09.008

22. Molecular Pharmaceutics (2011) doi: 10.1021/mp200100f

23. International Journal of Pharmaceutics (2011) doi:10.1016/j.ijpharm.2011.08.052

24. International Journal of Pharmaceutics (2011) doi:10.1016/j.ijpharm.2011.07.021

25. Molecular Pharmaceutics (2010) doi: 10.1021/mp100277h

26. Journal of Controlled Release (2013), http://dx.doi.org/10.1016/j.jconrel.2013.10.026

27. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.09.062

28. PLoS ONE (2013), doi:10.1371/journal.pone.0085003

29. Int J Pharmaceut (2013), http://dx.doi.org/10.1016/j.ijpharm.2013.12.016

30. Journal of Drug Targeting (2014), http://informahealthcare.com/doi/abs/10.3109/1061186X.2013.851683

31. ACS Nano (2014), doi: 10.1021/nn405155b

32. Molecular Pharmaceutics (2014), doi: 10.1021/mp400751g

33. Int J Pharmaceut (2014), http://dx.doi.org/10.1016/j.ijpharm.2014.03.012

34. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.03.012

35. Int J Pharmaceut (2014), http://dx.doi.org/10.1016/j.ijpharm.2014.04.008

36. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.03.036

37. Drug Delivery (2014), doi:10.3109/10717544.2014.903580

38. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.04.031

39. Pharm Res. (2014), doi: 10.1007/s11095-014-1400-9

40. Small (2014), doi: 10.1002/smll.201302786

41. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.04.117

42. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.06.022

43. Mol. Pharmaceutics (2014), dx.doi.org/10.1021/mp500113p

44. Vaccine (2014), http://dx.doi.org/10.1016/j.vaccine.2014.07.081

45. Journal of controlled release (2014), http://dx.doi.org/10.1016/j.jconrel.2014.09.029

46. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.09.008

47. International Journal of Nanomedicine 9, 5261–5271(2014).

48. Journal of pharmaceutical sciences (2014), doi: 10.1002/jps.24291

49. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.11.044

50. Int J Pharmaceut (2014), http://dx.doi.org/10.1016/j.ijpharm.2014.12.039

51. Acta Biomater (2015), http://dx.doi.org/10.1016/j.actbio.2015.01.010

52. Polym. Chem. (2015), doi: 10.1039/C4PY01422G

53. Biointerfaces (2015), http://dx.doi.org/10.1016/j.colsurfb.2015.02.041

54. ONCOLOGY LETTERS (2015), doi: 10.3892/ol.2015.3242

55. Acta Biomaterialia (2015), http://dx.doi.org/10.1016/j.actbio.2015.05.021

56. Drug Delivery (2015), http://informahealthcare.com/doi/abs/10.3109/10717544.2015.1040527

57. Journal of Drug Targeting (2015), doi:10.3109/1061186X.2015.1058800

58. Journal of drug targeting (2015), doi:10.3109/1061186X.2015.1064435

59. Nanomedicine (2015), doi:10.2217/nnm.15.106

60. Molecular Pharmaceutics (2015), doi: 10.1021/acs.molpharmaceut.5b00222

61. Bio-Medical Materials and Engineering 26 (2015), doi: 10.3233/BME-151384

62. ACS Appl. Mater. Interfaces (2015), doi: 10.1021/acsami.5b06043

63. International Journal of Pharmaceutics (2015), doi:10.1016/j.ijpharm.2015.12.013

64. RSC Advances (2015), doi: 10.1039/c5ra22233h

65. Applied Materials Interfaces (2015), doi: 10.1021/acsami.5b09934

66. Applied Materials & Interfaces (2016), doi: 10.1021/acsami.6b00036

67. PLoS ONE (2016), doi:10.1371/journal.pone.0149952

68. Applied materials and interfaces (2016), doi: 10.1021/acsami.6b00668

69. Biomaterials (2016), doi: 10.1016/j.biomaterials.2016.04.015

70. Nanoscale (2016), doi: 10.1039/C6NR01749E

71. Biomaterials (2016), doi: 10.1016/j.biomaterials.2016.05.037

72. Theranostics (2016), doi: 10.7150/thno.15164

73. Biomaterials (2016), http://dx.doi.org/10.1016/j.biomaterials.2016.06.048

74. Nanomedicine (2017), doi: 10.2217/nnm-2016-0408

75. J. Mater. Chem. B (2017), doi: 10.1039/C7TB01510K

76. Nanotechnology in Biomaterials (2017), doi: 10.1177/0885328217722740

77. Cancer Letters (2017), http://dx.doi.org/10.1016/j.canlet.2017.09.007

78. Colloids and Surfaces B: Biointerfaces (2017), https://doi.org/10.1016/j.colsurfb.2017.10.060

79. Photoacoustics (2017), https://doi.org/10.1016/j.pacs.2017.11.001

80. Applied Microbiology and Biotechnology (2018), https://doi.org/10.1007/s00253-018-8790-2

81. Artificial Cells, Nanomedicine, and Biotechnology (2018), doi: 10.1080/21691401.2018.1445093

82. Drug Delivery (2018), doi: 10.1080/10717544.2018.1446474

83. Neuropsychiatry (2018), doi: 10.4172/Neuropsychiatry.1000417

84. Biomaterials (2017), https://doi.org/10.1016/j.biomaterials.2017.09.013

Product Attributes

Size
5 x 1 mg, 10 mg
CAS number
100068-60-8
Probe cellular localization
Membrane/cell surface, Membrane/vesicular
For live or fixed cells
For fixed cells, For live/intact cells
Fixation options
Fix before staining (formaldehyde), Fix after staining (formaldehyde), Permeabilize before staining
Colors
Near-infrared
Excitation/Emission
748/780 nm

Documents, Protocols, SDS and COA

Citations

1. Biomaterials 34, 9171 (2013). http://dx.doi.org/10.1016/j.biomaterials.2013.08.039

2. J Control Release (2013) http://dx.doi.org/10.1016/j.jconrel.2013.10.002

3. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.09.094

4. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.09.089

5. International Journal of Nanomedicine 8, 2473–2485 (2013).

6. Bioconjugate Chemistry (2013) doi: 10.1021/bc400055h

7. International Journal of Pharmaceutics (2013), http://dx.doi.org/10.1016/j.ijpharm.2013.05.015

8. Pharm Res (2013) doi: 10.1007/s11095-013-1055-y

9. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.03.097

10. International Journal of Nanomedicine 8, 1573–1593 (2013)

11. International Journal of Nanomedicine 8, 1463–1476 (2013)

12. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.03.036

13. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.02.013

14. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2012.12.049

15. Biomaterials (2012), http://dx.doi.org/10.1016/j.biomaterials.2012.12.012

16. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2012.11.016

17. International Journal of Nanomedicine 7, 163–175 (2012)

18. J. Control. Release (2012) doi:10.1016/j.jconrel.2011.12.017

19. Pharm Res (2011) doi: 10.1007/s11095-011-0641-0

20. Biomaterials (2011) doi:10.1016/j.biomaterials.2011.10.035

21. International Journal of Pharmaceutics (2011) doi:10.1016/j.ijpharm.2011.09.008

22. Molecular Pharmaceutics (2011) doi: 10.1021/mp200100f

23. International Journal of Pharmaceutics (2011) doi:10.1016/j.ijpharm.2011.08.052

24. International Journal of Pharmaceutics (2011) doi:10.1016/j.ijpharm.2011.07.021

25. Molecular Pharmaceutics (2010) doi: 10.1021/mp100277h

26. Journal of Controlled Release (2013), http://dx.doi.org/10.1016/j.jconrel.2013.10.026

27. Biomaterials (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.09.062

28. PLoS ONE (2013), doi:10.1371/journal.pone.0085003

29. Int J Pharmaceut (2013), http://dx.doi.org/10.1016/j.ijpharm.2013.12.016

30. Journal of Drug Targeting (2014), http://informahealthcare.com/doi/abs/10.3109/1061186X.2013.851683

31. ACS Nano (2014), doi: 10.1021/nn405155b

32. Molecular Pharmaceutics (2014), doi: 10.1021/mp400751g

33. Int J Pharmaceut (2014), http://dx.doi.org/10.1016/j.ijpharm.2014.03.012

34. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.03.012

35. Int J Pharmaceut (2014), http://dx.doi.org/10.1016/j.ijpharm.2014.04.008

36. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.03.036

37. Drug Delivery (2014), doi:10.3109/10717544.2014.903580

38. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.04.031

39. Pharm Res. (2014), doi: 10.1007/s11095-014-1400-9

40. Small (2014), doi: 10.1002/smll.201302786

41. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.04.117

42. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.06.022

43. Mol. Pharmaceutics (2014), dx.doi.org/10.1021/mp500113p

44. Vaccine (2014), http://dx.doi.org/10.1016/j.vaccine.2014.07.081

45. Journal of controlled release (2014), http://dx.doi.org/10.1016/j.jconrel.2014.09.029

46. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.09.008

47. International Journal of Nanomedicine 9, 5261–5271(2014).

48. Journal of pharmaceutical sciences (2014), doi: 10.1002/jps.24291

49. Biomaterials (2014), http://dx.doi.org/10.1016/j.biomaterials.2014.11.044

50. Int J Pharmaceut (2014), http://dx.doi.org/10.1016/j.ijpharm.2014.12.039

51. Acta Biomater (2015), http://dx.doi.org/10.1016/j.actbio.2015.01.010

52. Polym. Chem. (2015), doi: 10.1039/C4PY01422G

53. Biointerfaces (2015), http://dx.doi.org/10.1016/j.colsurfb.2015.02.041

54. ONCOLOGY LETTERS (2015), doi: 10.3892/ol.2015.3242

55. Acta Biomaterialia (2015), http://dx.doi.org/10.1016/j.actbio.2015.05.021

56. Drug Delivery (2015), http://informahealthcare.com/doi/abs/10.3109/10717544.2015.1040527

57. Journal of Drug Targeting (2015), doi:10.3109/1061186X.2015.1058800

58. Journal of drug targeting (2015), doi:10.3109/1061186X.2015.1064435

59. Nanomedicine (2015), doi:10.2217/nnm.15.106

60. Molecular Pharmaceutics (2015), doi: 10.1021/acs.molpharmaceut.5b00222

61. Bio-Medical Materials and Engineering 26 (2015), doi: 10.3233/BME-151384

62. ACS Appl. Mater. Interfaces (2015), doi: 10.1021/acsami.5b06043

63. International Journal of Pharmaceutics (2015), doi:10.1016/j.ijpharm.2015.12.013

64. RSC Advances (2015), doi: 10.1039/c5ra22233h

65. Applied Materials Interfaces (2015), doi: 10.1021/acsami.5b09934

66. Applied Materials & Interfaces (2016), doi: 10.1021/acsami.6b00036

67. PLoS ONE (2016), doi:10.1371/journal.pone.0149952

68. Applied materials and interfaces (2016), doi: 10.1021/acsami.6b00668

69. Biomaterials (2016), doi: 10.1016/j.biomaterials.2016.04.015

70. Nanoscale (2016), doi: 10.1039/C6NR01749E

71. Biomaterials (2016), doi: 10.1016/j.biomaterials.2016.05.037

72. Theranostics (2016), doi: 10.7150/thno.15164

73. Biomaterials (2016), http://dx.doi.org/10.1016/j.biomaterials.2016.06.048

74. Nanomedicine (2017), doi: 10.2217/nnm-2016-0408

75. J. Mater. Chem. B (2017), doi: 10.1039/C7TB01510K

76. Nanotechnology in Biomaterials (2017), doi: 10.1177/0885328217722740

77. Cancer Letters (2017), http://dx.doi.org/10.1016/j.canlet.2017.09.007

78. Colloids and Surfaces B: Biointerfaces (2017), https://doi.org/10.1016/j.colsurfb.2017.10.060

79. Photoacoustics (2017), https://doi.org/10.1016/j.pacs.2017.11.001

80. Applied Microbiology and Biotechnology (2018), https://doi.org/10.1007/s00253-018-8790-2

81. Artificial Cells, Nanomedicine, and Biotechnology (2018), doi: 10.1080/21691401.2018.1445093

82. Drug Delivery (2018), doi: 10.1080/10717544.2018.1446474

83. Neuropsychiatry (2018), doi: 10.4172/Neuropsychiatry.1000417

84. Biomaterials (2017), https://doi.org/10.1016/j.biomaterials.2017.09.013

FAQs

Product shipping, storage, shelf life, & solubility

Bioscience kits
The guaranteed shelf life from date of receipt for bioscience kits is listed on the product information sheet. Some kits have an expiration date printed on the kit box label, this is the guaranteed shelf life date calculated from the day that the product shipped from our facility. Kits often are functional for significantly longer than the guaranteed shelf life. If you have an older kit in storage that you wish to use, we recommend performing a small scale positive control experiment to confirm that the kit still works for your application before processing a large number of samples or precious samples.

Antibodies and other conjugates
The guaranteed shelf life from date of receipt for antibodies and conjugates is listed on the product information sheet. Antibodies and other conjugates often are functional for significantly longer than the guaranteed shelf life. If you have an older conjugate in storage that you wish to use, we recommend performing a small scale positive control experiment to confirm that the product still works for your application before processing a large number of samples or precious samples.

For lyophilized antibodies, we recommend reconstituting the antibody with glycerol and antimicrobial preservative like sodium azide for the longest shelf life (note that sodium azide is not compatible with HRP-conjugates).

Chemicals, dyes, and gel stains
Biotium guarantees the stability of chemicals, dyes, and gel stains for at least a year from the date you receive the product. However, the majority of these products are highly stable for many years, as long as they are stored as recommended. Storage conditions can be found on the product information sheet or product safety and data sheet, material safety data sheet, and on the product label. Fluorescent compounds should be protected from light for long term storage.

If you have a Biotium compound that has been in storage for longer than one year that you wish to use, we recommend performing a small scale positive control experiment to confirm that the compound still works for your application before processing a large number of samples or precious samples.

Expiration date based on date of manufacture (DOM)
If your institution requires you to document expiration date based on date of manufacture for reagents, please contact techsupport@biotium.com for assistance.

Chemical products with special stability considerations:

Esters

Ester compounds include the following:

  • Succinimidyl esters (SE, also known as NHS esters), such as our amine-reactive dyes
  • Acetoxymethyl esters (AM esters), such as our membrane-permeable ion indicator dyes
  • Diacetate-modified dyes, like ViaFluor™ 405, CFDA, and CFDA-SE cell viability/cell proliferation dyes

Ester dyes are stable in solid form as long as they are protected from light and moisture. Esters are not stable in aqueous solution. Concentrated stock solutions should be prepared in anhydrous DMSO (see Biotium catalog no. 90082). Stock solutions in anhydrous DMSO can be stored desiccated at -20°C for one month or longer. Esters should be diluted in aqueous solution immediately before use. Succinimidyl esters (SE) should be dissolved in a solution that is free of amine-containing compounds like Tris, glycine, or protein, which will react with the SE functional group. AM esters and diacetate compounds should be dissolved in a solution that is free of serum, because serum could contain esterases that would hydrolyze the compound.

A note on CF® Dye succinimidyl ester stability

Succinimidyl esters (SE) are generally susceptible to hydrolysis, which can result in lower labeling efficiency. Many commercially available fluorescent dyes used for life science research are heavily sulfonated dyes which makes them particularly hygroscopic, worsening the hydrolysis problem. In addition, for several commercially available SE reactive dyes, the SE group is derived from an aromatic carboxylic acid, while the SE group in all of Biotium’s CF® Dyes is prepared from an aliphatic carboxylic acid. This structural difference reduces the susceptibility of CF® Dye SE reactive groups to hydrolysis, resulting in relatively stable reactive dyes with consistently higher labeling efficiency compared to other SE derivatives of other fluorescent dyes.

Maleimides, MTS and thiosulfate dyes
Like the succinimidyl ester dyes, these dyes are also susceptible to hydrolysis, although generally to a much lower degree. Thus, for long term storage, anhydrous DMSO is recommended for making stock solutions.

Other reactive dyes
Amines, aminooxy (also known as oxylamine), hydrazide, azide, alkyne, BCN, and tyramide reactive dyes, as well as dye free acids, are generally stable in aqueous solution when stored at -20°C for 6-12 months or longer, as long as no compounds are present that may react with the dye’s functional group. See the product information sheets for specific reactive dyes more information.

Coelenterazines and D-luciferin

Coelenterazines are stable in solid form when stored as recommended; they are not stable in aqueous solution. Concentrated coelenterazine stock solutions (typically 1-100 mg/mL) should be prepared in ethanol or methanol; do not use DMSO or DMF to dissolve coelenterazines, because these solvents will oxidize the compounds. Ethanol or methanol stocks of coelenterazine can be stored at -20°C or below for six months or longer; alcohol stocks may evaporate during storage, so use tightly sealing screw cap vials and wrap the vials with Parafilm for long term storage. Propylene glycol also can be used as a solvent to minimize evaporation. If the solvent evaporates, the coelenterazine will still be present in the vial, so note the volume in the vial prior to storage so that you can adjust the solvent volume to correct for evaporation if needed. Prepare working solutions in aqueous buffers immediately before use. Coelenterazines are stable for up to five hours in aqueous solution.

Aquaphile™ coelenterazines are water soluble formulations of coelenterazines. They are stable in solid form when stored as recommended. Aquaphile™ coelenterazines should be dissolved in aqueous solution immediately before use. They are stable for up to five hours in aqueous solution.

Note that coelenterazines are predominantly yellow solids, but may contain dark red or brown flecks. This does not affect product stability or performance. If your coelenterazine is uniformly brown, then it is oxidized and needs to be replaced.

D-luciferin is stable in solid form and as a concentrated stock solution when stored as recommended; it is not stable at dilute working concentrations in aqueous solution. Prepare concentrated D-luciferin stock solutions (typically 1-100 mg/mL) in water, and store in aliquots at -20°C or below for six months or longer. Prepare working solutions immediately before use.

For dyes or reagents that are supplied lyophilized (as solids), it is hard to compare quantities based on appearance of the dye in the tube, because during the lyophilization process the dye can dry down in different ways, either spread out all over the tube, clumped together, or coating the sides or bottom of the tube. Centrifugation of the tube may not help in collecting the dye solid to the bottom of the tube as this generally works for solutions. However, lyophilized solids are packaged based on highly accurate absorbance measurement of the reagent solution prior to drying, so the vial will contain the correct amount of dye.

Biotium ships all antibodies (primary, secondary and conjugates) at room temperature. We guarantee their quality and performance under these conditions based upon our stability testing. Antibodies were subjected to accelerated stability testing by storing them at various temperatures (4°C, room temperature, or 37°C) for 1 week to mimic simulated shipping conditions and tested in immunostaining experiments. All antibodies showed the expected brightness and specificity, even after storage at sub-optimal temperatures for a week or longer. You can also download our Product Storage Statement here.

In line with our goal to be more environmentally friendly by reducing the use of excess packaging, and lowering shipping costs for our customers, products that have passed our stability testing are shipped at room temperature.

Once you have received the antibody vial, please follow the long-term storage instructions on the product information (PI) sheet.

Can’t find your answer?

Contact Us